Evaluate Effective Payment Models, Assess Value & Advance Reimbursement Strategies to Establish Therapies in the Rapidly Evolving Obesity & CVRM Market

Welcome to the inaugural Market Access for Obesity & CVRM Therapeutics Summit

With anti-obesity medications in phase 3 trials from 4 pharmaceutical giants: Lilly, Novo Nordisk, Boehringer Ingelheim and Amgen, the obesity and weight loss field is poised to be shaken up once again.

However, even with increased scientific insights and the imminent arrival of these powerful therapies, substantial barriers remain, threatening to restrict patient access to treatments that could fundamentally alter weight management and the future of cardiovascular, renal, and metabolic healthcare.

Navigating the complex and everchanging landscape, coupled with an enormous patient population, market access for therapies to treat obesity and its comorbidities present formidable challenges. In a time of uncertainty around government policies and an unrecognizable healthcare landscape, the Market Access for Obesity & CVRM Therapeutics Summit will unite biopharmaceutical players, Payers, government organizations, and consultants all under one roof to assess strategies to establish new therapies in the market, leaving you with tangible insights to take back to your team.